急性早幼粒細胞白血病

急性早幼粒細胞白血病
急性早幼粒細胞白血病
類型	急性骨髓性白血病、bilineal acute myeloid leukemia[*]、疾病
分類和外部資源
醫學專科	血液學和腫瘤學
ICD-11	XH1A50
OMIM	612376
DiseasesDB	34779
eMedicine	197802
Orphanet	520
	[編輯此條目的維基數據]

急性早幼粒細胞白血病（acute promyelocytic leukemia，APML，APL）又稱急性前髓細胞白血病，是一種亞型急性骨髓性白血病^[1]。1957年，法國和挪威的醫生首次提到急性早幼粒細胞白血，當時患者的生存期不到一周^[2]。隨新藥發明與演進，預後已大大改善；現今患者的10年生存率估計約為80-90%^[3]^[4]。

發病機制

急性早幼粒細胞白血病的特徵是染色體易位，涉及17號染色體 (RARA) 上的視黃酸受體α基因^[1]。 95% 的 APL 病例中，17號染色體上的維甲酸受體-α (RARA) 基因與15號染色體上的早幼粒細胞白血病基因 (PML) 相互易位，這種易位表示為 t(15;17)(q24) ;q21)^[1]. RAR 受體依賴於視黃酸(Retinoic acid)來調節轉錄^[1]。

參考文獻

^ ^1.0 ^1.1 ^1.2 ^1.3 Kotiah, SD. Acute Promyelocytic Leukemia. Medscape Reference. WebMD. 3 June 2013 [14 January 2014]. （原始內容存檔於2014-01-16）.
^ Coombs, C. C.; Tavakkoli, M.; Tallman, M. S. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer Journal. 2015-04-17, 5 (4): e304. PMC 4450325  . PMID 25885425. doi:10.1038/bcj.2015.25 （英語）.
^ Adès, L; Guerci, A; Raffoux, E; Sanz, M; Chevallier, P; Lapusan, S; Recher, C; Thomas, X; Rayon, C. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. March 2010, 115 (9): 1690–1696. PMID 20018913. doi:10.1182/blood-2009-07-233387.
^ C C, Coombs. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer Journal. 17 April 2015, 5 (4): 304. PMC 4450325  . PMID 25885425. doi:10.1038/bcj.2015.25.

[MSR-1] 1.0 ^1.1 ^1.2 ^1.3 Kotiah, SD. Acute Promyelocytic Leukemia. Medscape Reference. WebMD. 3 June 2013 [14 January 2014]. （原始內容存檔於2014-01-16）.

[:0-2] Coombs, C. C.; Tavakkoli, M.; Tallman, M. S. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer Journal. 2015-04-17, 5 (4): e304. PMC 4450325  . PMID 25885425. doi:10.1038/bcj.2015.25 （英語）.

[Blood2010-3] Adès, L; Guerci, A; Raffoux, E; Sanz, M; Chevallier, P; Lapusan, S; Recher, C; Thomas, X; Rayon, C. Very long-term outcome of acute promyelocytic leukemia after treatment with all-trans retinoic acid and chemotherapy: the European APL Group experience. Blood. March 2010, 115 (9): 1690–1696. PMID 20018913. doi:10.1182/blood-2009-07-233387.

[4] C C, Coombs. Acute promyelocytic leukemia: where did we start, where are we now, and the future. Blood Cancer Journal. 17 April 2015, 5 (4): 304. PMC 4450325  . PMID 25885425. doi:10.1038/bcj.2015.25.

[1]

[2]

[3]

[4]